

Urticaria

Patient Enrollment and Prescription

PATIENT INFORMATION

Patient Name _____
 DOB ____/____/____ SSN _____ Gender _____
 Weight _____ Height _____ Phone _____
 Address _____
 City, State, Zip _____
 Cell Phone _____ E-Mail _____
PLEASE PROVIDE COPY OF PATIENT'S PRESCRIPTION INSURANCE CARD WITH ENROLLMENT FORM
 Insurance Co. Name _____
 Insurance Co. Phone _____ Group# _____
 Policy Holder Name _____
 Policy Holder Employer _____
 Relationship to Patient _____
 ID# _____ RxBIN _____ PCN _____


PRESCRIBER INFORMATION

Prescriber's Name _____
 Practice Name _____
 DEA _____ NPI _____
 Address _____
 City, State, Zip _____
 Phone _____ Fax _____
 Office Contact Person _____
 Office Contact EMAIL _____
 Prescription Date _____ Date Needed _____
 With my signature on this form, I also authorize use of Gentry Health's Services which includes serving as my prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.
Prescriber Signature _____
 Ship to: ☐ Patient ☐ Prescriber's Office ☐ Discount Drug Mart

PLEASE PROVIDE ALL RELEVANT CHART NOTES FOR INSURANCE PURPOSES

Medical Information (DO NOT COMPLETE IF CHART NOTES ARE PROVIDED)

Diagnosis _____ ICD-10 Code _____
 Date of Diagnosis _____ Body Surface Affected: _____ %
☐ Itch NRS (0 -10): _____
☐ Urticaria symptoms persistent more than 6 weeks?
 Drug Allergies _____ Latex Allergy? ☐ YES ☐ NO
 Failed Prior therapies?
☐ Topical Corticosteroids:
 _____ to _____
 _____ to _____
☐ Topical therapy not appropriate
 Reason: _____
☐ Systemic Corticosteroids, Immunosuppressants and/or Phototherapy:
 _____ to _____
 _____ to _____
☐ Systemic corticosteroids not appropriate
☐ Oral H1 antihistamines
☐ Immunosuppressants not appropriate
☐ Phototherapy not appropriate
 Reason: _____



☐ Scalp ☐ Groin ☐ Face
☐ Other: _____

Additional Comments _____

PRESCRIPTION INFORMATION

(please indicate days supply if different than suggested days supply)

☐ **Dupixent® (dupilumab)** ☐ Syringe ☐ Pen
☐ ADULT STARTER: 600MG SQ at week 0, 300MG SQ Q2 weeks Quantity: 4 Refills _____
☐ ADULT MAINTENANCE: 300MG SQ once every 2 weeks Quantity: 2 Refills _____
☐ PED (12-17 yrs) 30-59kg: 400MG SQ week 0, 200mg Q2 weeks Quantity: 2 Refills _____
☐ PED (12-17 yrs) ≥60kg: 600MG SQ week 0, 300mg Q2 weeks Quantity: 2 Refills _____
☐ **Rhapsido® (remibrutinib)** ☐ 25mg Tablet
 Directions: Take 1 tablet twice daily Qty: 60 tablets Refills _____
☐ **XOLAIR® (omalizumab)** ☐ Pre-filled Syringe ☐ Autoinjector
☐ 75mg ☐ 150mg ☐ 300mg
☐ 4 week dosing: Inject subcutaneously every four weeks Quantity: _____ Refills _____